Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-08-18

FDA Approved: JUNEL 21 DAY — Supplemental Application (Teva Pharmaceuticals USA, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Junel 21 Day (norethindrone acetate and ethinyl estradiol) from Teva Pharmaceuticals USA, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Junel 21 Day (NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL)

Snippet

SUPPL AP for JUNEL 21 DAY (NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL)